## Arran K Turnbull

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3490454/publications.pdf

Version: 2024-02-01

430442 433756 1,070 35 18 31 citations h-index g-index papers 37 37 37 1955 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Characterisation of the Stromal Microenvironment in Lobular Breast Cancer. Cancers, 2022, 14, 904.	1.7	13
2	Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research, 2022, 28, 3618-3629.	3.2	12
3	Risk of chemotherapy-related amenorrhoea (CRA) in premenopausal women undergoing chemotherapy for early stage breast cancer. Breast Cancer Research and Treatment, 2021, 186, 237-245.	1.1	6
4	Current trends in the treatment of HR+/HER2+ breast cancer. Future Oncology, 2021, 17, 1665-1681.	1.1	26
5	The Signal Transducer IL6ST (gp130) as a Predictive and Prognostic Biomarker in Breast Cancer. Journal of Personalized Medicine, 2021, $11$ , $618$ .	1.1	11
6	Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine. Journal of Personalized Medicine, 2021, 11, 664.	1.1	11
7	Diagnostic accuracy of core biopsy in patients presenting with axillary lymphadenopathy and suspected non-breast malignancy. European Journal of Surgical Oncology, 2021, 47, 1575-1580.	0.5	1
8	A Novel Approach for the Discovery of Biomarkers of Radiotherapy Response in Breast Cancer. Journal of Personalized Medicine, 2021, 11, 796.	1.1	7
9	The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer. Journal of Personalized Medicine, 2021, 11, 1073.	1.1	7
10	Primary acinic cell carcinoma of the breast is associated with a poor outcome: A case report and literature review. Molecular and Clinical Oncology, 2021, 16, 43.	0.4	8
11	The Importance of the Tumor Microenvironment and Hypoxia in Delivering a Precision Medicine Approach to Veterinary Oncology. Frontiers in Veterinary Science, 2020, 7, 598338.	0.9	9
12	Comparative Analysis of the Development of Acquired Radioresistance in Canine and Human Mammary Cancer Cell Lines. Frontiers in Veterinary Science, 2020, 7, 439.	0.9	8
13	Factors affecting the number of sentinel lymph nodes removed in patients having surgery for breast cancer. Breast Cancer Research and Treatment, 2020, 184, 335-343.	1.1	7
14	Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer. Molecular Cancer Therapeutics, 2020, 19, 680-689.	1.9	44
15	Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer. Frontiers in Oncology, 2020, 10, 628.	1.3	34
16	Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer. Frontiers in Oncology, 2020, 10, 617.	1.3	78
17	Evidence-based guidelines for managing patients with primary ER+ HER2â <sup>-,</sup> breast cancer deferred from surgery due to the COVID-19 pandemic. Npj Breast Cancer, 2020, 6, 21.	2.3	42
18	HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer. Breast Cancer Research, 2019, 21, 10.	2.2	48

#	Article	IF	Citations
19	On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research, 2019, 21, 73.	2.2	32
20	Development and characterisation of acquired radioresistant breast cancer cell lines. Radiation Oncology, 2019, 14, 64.	1.2	72
21	Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours. Breast Cancer Research, 2019, 21, 2.	2.2	29
22	The evolving role of receptors as predictive biomarkers for metastatic breast cancer. Expert Review of Anticancer Therapy, 2019, 19, 121-138.	1.1	11
23	Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment. BMC Cancer, 2018, 18, 636.	1.1	66
24	Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast. Cancer Treatment Reviews, 2017, 55, 163-172.	3.4	29
25	Margin width and local recurrence after breast conserving surgery for ductal carcinoma in situ. European Journal of Surgical Oncology, 2017, 43, 2029-2035.	0.5	9
26	Pre-operative Endocrine Therapy. Current Breast Cancer Reports, 2017, 9, 202-209.	0.5	17
27	Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells. Oncotarget, 2017, 8, 42857-42875.	0.8	62
28	Novel histopathologic feature identified through image analysis augments stage II colorectal cancer clinical reporting. Oncotarget, 2016, 7, 44381-44394.	0.8	20
29	Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models. British Journal of Cancer, 2016, 114, 905-916.	2.9	42
30	Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies. Scientific Reports, 2016, 6, 29434.	1.6	13
31	A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models. Oncotarget, 2015, 6, 25677-25695.	0.8	115
32	Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. Journal of Clinical Oncology, 2015, 33, 2270-2278.	0.8	96
33	Personalized medicine in cancer: where are we today?. Future Oncology, 2015, 11, 2795-2798.	1.1	10
34	Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers. PLoS ONE, 2015, 10, e0144708.	1.1	40
35	Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy. Cancer Research, 2014, 74, 5371-5376.	0.4	34